Search

everythinglearnresearchcommunity

for

Search:↓

User asks about Pyrilutamide for hair loss and its cost. Questions include legitimacy of selleckchem, vehicle to use, and storage.

Concerns about using 0.3% topical finasteride due to potential side effects like decreased libido and gynecomastia. Suggestions include using less than 1ml or considering 1mg oral finasteride.

A user's 3-month progress with a combination of finasteride, minoxidil and dermarolling for hair loss; other users shared their experiences and advice.

Clascoterone's full trial results are expected by mid-July 2026, but skepticism exists about timely release. Clascoterone is available at 5% from some telehealth companies.

A user shared impressive hair regrowth results after 4 months using topical minoxidil, oral finasteride, and 3 PRP sessions. They plan to continue with these treatments and add dermastamping.

The potential of using Verteporfin to prevent hair loss scars and possible regrowth, with two doctors currently testing it, although the price of a 15mg bottle is expensive.

The conversation is about whether the phase 2 results for pyrilutamide, a potential hair loss treatment, were presented at a dermatology convention and inquiries about the completion of phase 3 trials. Specific treatments mentioned include pyrilutamide.

The user takes 1 mg finasteride three times a week, topical minoxidil daily, and Saw Palmetto both topically and orally on non-finasteride days. They recently added 1 g of pumpkin seed oil daily to improve hair thickness and are seeking advice on dosing and cycling Saw Palmetto.

Dutasteride significantly improved hair health and reduced shedding for a woman with PCOS and hyperandrogenism, without causing depression or anxiety, unlike finasteride. Dutasteride also helped with PMDD symptoms and had no side effects, though it changed hair texture.

The user experienced good crown progress in 3 months using finasteride, collagen, vitamins B, C, D, zinc, and dermarolling. They are pleased with the results after a hair transplant on the front and mid scalp.

The user has seen no regrowth after 1 year and 2 months on finasteride, despite increasing the dose, and is inquiring about the potential of future treatments like verteporfin and gt20029 for hair regrowth.

The conversation discusses hair loss treatments, specifically RU58841, with mentions of side effects from finasteride and dutasteride. Alternatives like Pyri, KX-826, and Breezula are also mentioned.

HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.

The user has experienced limited hair regrowth using 1mg oral finasteride, topical minoxidil foam, and occasional dermarolling since August 2023. They are considering switching to dutasteride, adding oral minoxidil 2.5 mg, and RU58841 to improve results.

The conversation discusses the potential of a new hair loss treatment, GT20029, which may prevent hair loss by destroying androgen receptors on the scalp. Users express hope for the treatment's success and speculate on its usage routine, effectiveness, and possible side effects.

The conversation is about the anticipation and uncertainty regarding the release of GT20029 Phase 2 results for hair loss treatment. Users express hope for its effectiveness and minimal side effects compared to other treatments like Pyri and HMI115.

Pelage PP405 is a new hair loss treatment in trials, potentially reactivating dormant hair follicles without affecting hormones. Results are expected in February 2025, offering an alternative to minoxidil and finasteride.

The conversation is about whether a doctor is needed for injections of a product called SCUBE3 for hair loss. No specific treatments were discussed.

Topical finasteride (P-3074) can inhibit scalp DHT by up to 70%, with some users experiencing systemic absorption similar to oral use. Users discuss varying application frequencies and concentrations, with some noticing side effects when overused.

Shiseido RCH-01 and Replicel's upcoming trial data release. Users discuss expected release timelines and clarify quarter dates.

The user seeks alternatives to Propylene Glycol (PG) for delivering topical finasteride due to scalp irritation. They consider using Propanediol 1,3 and ask for other suggestions.

The conversation is about the effectiveness of peptides for hair loss and the user considering using GHK-Cu, CJC-1295, and BPC-157 for treatment.

Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss. PP405 is still under evaluation for safety.

KX-826 hair loss treatment completed trials with mild side effects. GT20029 may be ultimate cure, destroying androgen receptors causing baldness.

Topical finasteride may have higher systemic absorption and lower efficacy when using a Propylene Glycol/Ethanol formulation compared to the hydroxypropyl chitosan (HPCH) formulation. The safety profile of topical finasteride relies heavily on the HPCH formulation, and using standard solutions might lead to different pharmacokinetics.

Clascoterone's European release is expected in Q4 2026, with FDA approval anticipated by mid-2027. The discussion includes questions about the approval timeline and potential acceleration due to unmet needs.

New hair loss treatments like VDPHL01, PP405, Gt20029, and Breezula are anticipated, with VDPHL01 possibly releasing in 2027/28. Current treatments include finasteride, dutasteride, and minoxidil, but new options are eagerly awaited.

The conversation discusses the potential risks and considerations of purchasing raw Clascoterone powder from Made-In-China to create a DIY topical solution for hair loss. Concerns include fake products, low purity, and contamination, with a request for experiences and advice on reliable suppliers.

The conversation discusses hair loss treatments, focusing on a new slow-release oral minoxidil compared to topical minoxidil and finasteride. The results show that twice-daily dosing of the new treatment is slightly more effective than once-daily, but concerns about cost, side effects, and the accuracy of reported results remain.

A 25-year-old shared their 3-month progress using a combination of 1mg finasteride and 5% minoxidil for hair loss. The images show noticeable improvement in hair density.